FibroBiologics secures European patent for gene therapy that regenerates cartilage

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

FibroBiologics announced that the European Patent Office has granted European Patent No. EP 3043825 B1, which the company says contains 12 claims covering compositions comprising one or more expression vectors encoding therapeutic polynucleotides, including Sox9, for use in treating individuals in need of cartilage repair.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE